- In June 2023, a strategic partnership was announced between tech giant Philips and med-tech corporation Biotronik. The collaboration aims to enhance patient care accessibility by combining Philips' advanced technologies with Biotronik's expertise in medical devices. This alliance is expected to improve healthcare delivery and expand access to cutting-edge treatment options for patients worldwide
- In October 2023, MicroPort CRM, a leading cardiac rhythm management company based in France, launched its ULYS Implantable Cardioverter Defibrillator and INVICTA defibrillation lead in Japan. These products are MRI-compatible at 1.5T and 3T when used together as a system. This launch is expected to enhance MicroPort CRM's product portfolio and drive revenue growth in the Japanese market
- In October 2023, Medtronic plc received FDA clearance for its Aurora EV-ICD MRI SureScan and Epsila EV MRI SureScan defibrillation leads, designed to treat rapid heart rhythms that can lead to sudden cardiac arrest (SCA). This approval expands Medtronic’s product portfolio, enhancing its ability to provide advanced solutions for heart rhythm disorders. As a result, the company’s serviceability and market position are expected to improve significantly
- In September 2022, Kauvery Hospital launched the Restart Heart Foundation in Chennai, India, with the deployment of over 100 automated external defibrillators (AEDs) at key locations throughout the city. This initiative aims to improve access to life-saving devices for those experiencing sudden cardiac arrest. The foundation's efforts are expected to enhance public health preparedness and raise awareness about heart emergencies in the region
- In August 2022, Medtronic announced successful trial results for its investigational extravascular implantable cardioverter defibrillator (EV ICD) system. Unlike traditional transvenous ICDs, the EV ICD places its lead outside the heart and veins, beneath the sternum, through a minimally invasive surgery. This innovative design aims to reduce risks associated with conventional ICDs, offering a safer alternative for patients requiring cardiac rhythm management
Frequently Asked Questions
The market is segmented based on Global Implantable Cardioverter Defibrillators (ICDs) Market Segmentation, By Product (Biventricular Implantable Cardioverter Defibrillators, Single Chambered, and Dual Chambered), Procedure (Subcutaneous Implantable Cardioverter Defibrillators, and Trans-Venous Implantable Cardioverter Defibrillators), Applications (Bradycardia, Tachycardia, Heart Failure, and Others), End- User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others) – Industry Trends and Forecast to 2032
.
The Global Implantable Cardioverter Defibrillators Icds Market size was valued at USD 3.92 USD Billion in 2024.
The Global Implantable Cardioverter Defibrillators Icds Market is projected to grow at a CAGR of 2.9% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..